story of the week
PFS and OS in Patients With Advanced HER2+ Breast Cancer Treated With T-DM1 After Previous Treatment With Pertuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancers
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Progression-Free Survival and Overall Survival in Patients With Advanced HER2-Positive Breast Cancer Treated With Trastuzumab Emtansine (T-DM1) After Previous Treatment With Pertuzumab
Cancers (Basel) 2020 Oct 17;[EPub Ahead of Print], LL Michel, AD Hartkopf, PA Fasching, HC Kolberg, P Hadji, H Tesch, L Häberle, J Ettl, D Lüftner, M Wallwiener, V Müller, MW Beckmann, E Belleville, B Volz, H Huebner, P Wimberger, C Hielscher, C Mundhenke, C Kurbacher, R Wuerstlein, M Untch, F Overkamp, J Huober, W Janni, FA Taran, MP Lux, D Wallwiener, SY Brucker, A Schneeweiss, TN FehmFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.